Search Within

Sloan Kettering Institute Postdocs

Formats
  1. Journal Article (8036)
  2. Meeting Abstract (3693)
  3. Review (630)
  4. Editorial (262)
  5. Book Section (195)
  6. Conference Paper (161)
  7. Research Letter (139)
  8. Correspondence (68)
  9. Miscellaneous (67)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. GSK Faculty (6363)
  2. Department of Medicine (4809)
  3. Sloan Kettering Institute Faculty (3570)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (3037)
  5. Surgery (2633)
  6. Solid Tumor Oncology Division (2604)

More Groups

People
  1. Britta Weigelt (376)
  2. Jorge Reis-Filho (328)
  3. Mithat Gonen (318)
  4. Marc Ladanyi (309)
  5. Michael Berger (288)
  6. Joseph Deasy (285)

More People

Years
  1. 2026 (1)
  2. 2025 (697)
  3. 2024 (1080)
  4. 2023 (1152)
  5. 2022 (1366)
  6. 2021 (1179)

More Years

Publications
  1. Blood (680)
  2. Cancer Research (543)
  3. Journal of Clinical Oncology (431)
  4. Journal of Nuclear Medicine (271)
  5. Annals of Surgical Oncology (264)
  6. Clinical Cancer Research (249)

More Publications

Publishers
  1. Nature Publishing Group (1349)
  2. Elsevier Inc. (1106)
  3. American Association for Cancer Research (1058)
  4. Springer (840)
  5. American Society of Hematology (740)
  6. Cell Press (740)

More Publishers

Results (13287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary tolerability assessment of naxitamab (humanized anti-GD-2 monoclonal antibody) therapy in a phase 2 osteosarcoma trial
    Meeting Abstract

    Dela Cruz, F.; Chou, A.; Roberts, S.; Mauguen, A.; Bonura, J.; Hilliard, J.; Namuduri, M.; Ortiz, M.; Slotkin, E.; Wexler, L.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for consolidating >= 2nd complete remission of high-risk neuroblastoma
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Clonal evolution in metastatic rhabdomyosarcoma
    Meeting Abstract

    Kinnaman, M.; Makohon-Moore, A.; Bouvier, N.; Glodzik, D.; Levine, M.; Papaemmanuil, E.; Dela Cruz, F.; Wexler, L.; Kung, A.; Iacobuzio-Donahue, C.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • A curative approach to central nervous system metastases of neuroblastoma
    Meeting Abstract

    Kramer, K.; Kushner, B.; Modak, S.; Pandit-Taskar, N.; Mauguen, A.; Tomlinson, U.; Wolden, S.; Zanzonico, P.; Humm, J.; Haque, S.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • CAR T-cells followed by CD34-selected T-cell depleted (TCD) ALLO-HSCT is associated with low toxicity and favorable overall survival
    Meeting Abstract

    Fabrizio, V.; Boulad, F.; Cancio, M.; Margossian, S.; Mauguen, A.; Prockop, S.; Scaradavou, M.; Shah, N.; Spitzer, B.; Stieglitz, E.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • A phase I study of convection-enhanced delivery of (124)I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Taskar, N.; Zhou, Z.; Zanzonico, P.; Donzelli, M.; Lyashchenko, S. K.; Haque, S.; Thakur, S. B.; Cheung, N. K. V.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) with elderly cancer patients: A systematic review
    Meeting Abstract

    Sparano, F.; Aaronson, N. K.; Sprangers, M. A. G.; Fayers, P.; Pusic, A.; Kieffer, J. M.; Rees, J.; Wan, C.; Pezold, M.; Fuzesi, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Does the quality of patient-reported outcomes (PROs) assessment in randomized controlled trials (RCTs) differ across cancer types and overtime? A pooled analysis of 610 RCTs published between 2004 and 2018
    Meeting Abstract

    Sparano, F.; Aaronson, N. K.; Sprangers, M. A. G.; Fayers, P.; Pusic, A.; Kieffer, J. M.; Rees, J.; Wan, C. H.; Pezold, M.; Fuzesi, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save